Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

EQS-News: Biotest AG / Key word(s): Quarter Results
Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

07.05.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

* Product sales increased by 17.7% to Euro 138.0 million

* EBIT increased to Euro 52.8 million

* Successful completion Fibrinogen study

Dreieich, 07 May 2024. The Biotest Group recorded revenue of EUR 215.2 million
in the first quarter of the 2024 financial year. This represents an increase
of 83.6 % compared to revenue of EUR 117.2 million in the same period of the
previous year.

Product sales increased by 17.7 % to EUR 138.0 million. Additionally, revenue
due to sales from technology disclosure and development services for
Grifols, S.A. as part of the technology transfer and licensing agreement
amounted to
EUR 77.2 million.

The new intravenous immunoglobulin Yimmugo® had a positive impact with an
increase in sales of EUR 7.5 million to EUR 11.1 million, which was successfully
launched on the market in November 2022 and is now the first commercial
preparation to be manufactured in an innovative production process at the
new Biotest Next Level production facility at the Dreieich site in Germany.
Intratect® also contributed to the increase in sales.

EBIT for the first quarter of 2024 amounted to EUR 52.8 million, a significant
improvement on the first quarter of the previous year (prior year period: EUR
- 9.1 million). This includes expenses of EUR 22.9 million for the ramp-up of
production capacity at the Biotest Next Level facility (prior year period: EUR
22.2 million). The improvement in EBIT is mainly due to the earnings effect
from technology disclosure and development services for Grifols, S.A.
amounting to EUR 70.3 million.

The financial result for the first quarter of the current year deteriorated
by EUR -1.4 million to EUR -10.7 million (prior-year period: EUR -9.3 million).

The Biotest Group's earnings after taxes improved to EUR 29.5 million in the
first quarter of 2024 after EUR -20.4 million in the same quarter of the
previous year due to the influencing factors described above. This results
in earnings per ordinary share of EUR 0.74 after EUR -0.53 in the same period of
the previous year.

One component of Biotest's strategy is the continuous expansion of the
company's own plasma collection network in Europe. This is intended to
ensure a sufficient supply of human blood plasma, the most important raw
material for Biotest's preparations. By the end of the first quarter of
2024, Biotest operated 37 plasma collection centres in Germany, Hungary and
the Czech Republic. The opening of further plasma centres is planned for
2024. Another plasma collection centre was thus opened in Germany in April
2024. In addition, Biotest is participating financially in the establishment
of further plasma centers with partners.

Following the approval of Yimmugo® in Germany, Austria and the United
Kingdom, Biotest is seeking approval for the attractive US target market.
The approval process is already well advanced. In September 2023, the US
Food and Drug Administration (FDA) informed Biotest that it accepted the
Biologics License Application for Yimmugo® with the indication Primary
Immunodeficiencies for review. The FDA inspection of the Biotest Next Level
facility took place in December 2023. Further steps to obtain the Biologics
License Application for Yimmugo® will be taken in the course of 2024.

With Fibrinogen concentrate and Trimodulin, two further new plasma proteins
are in advanced development. Biotest successfully completed the Phase III
trials for the use of Fibrinogen concentrate in the indications of
congenital and acquired fibrinogen deficiency in February 2024, which
represents an important milestone for the Biotest Next Level project at the
Dreieich site. The first applications for marketing authorization are
planned in the important markets in Europe and the USA.

Biotest has also started a Phase III trial with Trimodulin in the indication
severe community-acquired pneumonia (sCAP). The first patient was treated
with sCAP in an intensive care unit as part of the Phase III ESsCAPE study.
In addition, the ongoing multinational TRICOVID trial was opened for the
inclusion of patients with pneumonia caused by any type of pathogen and the
first patient was treated as part of this expansion in December 2023.
Biotest is also moving ahead with its research activities for existing
products in order to improve patient care. We are striving for greater
operational excellence in research and development as well as in procurement
management and production. To this end, we will continue to focus on
selected measures to make processes in all areas of the company even more
efficient.

Outlook:

For the 2024 financial year, the Board of Management is aiming to increase
revenue in the upper single-digit percentage range compared to 2023, taking
into account the revenue from the technology disclosure and the development
services for Grifols, S.A. This increase in revenue is possible due to the
ramp-up of the Yimmugo® production facility within Biotest Next Level.

Accordingly, the Board of Management expects an operating result (EBIT) in
the range of EUR 80 to 100 million for 2024. As a result, the Board of
Management expects a slightly improved return on capital employed (ROCE) in
2024 compared to the 2023 financial year and a positive cash flow from
operating activities significantly above the previous year's level.

The quarterly statement as of March 31, 2024 can be found on the company's
website at the following link Quarterly Reports (biotest.com).

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumin based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. Biotest has more than 2,600 employees worldwide. The ordinary and
preference shares of Biotest AG are listed in the Prime Standard on the
German stock exchange. Since May 2022, Biotest is part of the Grifols Group,
Barcelona, Spain (www.grifols.com).

Biotest AG will now also be publishing official press releases via X. You
can find us at: https://twitter.com/BiotestAG

IR contact

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201

Preference shares: securities' ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart,
Tradegate

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.


---------------------------------------------------------------------------

07.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Biotest AG
                   Landsteinerstraße 5
                   63303 Dreieich
                   Germany
   Phone:          0 61 03 - 8 01-0
   Fax:            0 61 03 - 8 01-150
   E-mail:         ir@biotest.com
   Internet:       www.biotest.de
   ISIN:           DE0005227235, DE0005227201
   WKN:            522723, 522720
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1896701

End of News EQS News Service
---------------------------------------------------------------------------

1896701 07.05.2024 CET/CEST